
T-E Pharma Holding owns two subsidiaries: Immunwork, Inc. and T-E Meds, Inc. Immunwork, founded in 2014, is dedicated to the research, development and commercialization of innovative therapeutics based on our proprietary “T-E pharmaceuticals” platform. The drug-design platform is employed in the construction of ultra-long-acting peptide therapeutics, antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), and other advanced pharmaceutical modalities. To focus development efforts in the ADC/ARC field, Immunwork established T-E Meds, Inc. in 2022 to take over and further…
Built from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Annual Revenue$10M to $25M
Estimated OwnershipPrivateMatching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.